Free press releases distribution network?

Agency / Source: Becton, Dickinson and Company

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BD Biosciences Announces Spring 2011 Winners of Research Grant Program - Seven scientists receive immunology research grants
BD Biosciences Announces Spring 2011 Winners of Research Grant Program


PRZOOM - /newswire/ - San Jose, CA, United States, 2011/07/12 - Seven scientists receive immunology research grants. NYSE: BDX

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today the spring 2011 winners of its Research Grant Program.

“Basic immunology research has proved to be a rich source of translational medicine,” said Robert Balderas, Vice President, Biological Sciences, BD Biosciences. “BD is pleased to support the work of these scientists who are investigating immunologic factors that may one day be harnessed to treat a wide range of serious diseases.”

An independent panel of distinguished scientists selected the winners. Each recipient will receive a $10,000 grant of research reagents to help them conduct their studies.

The winners of the BD Biosciences Research Grant Program for the spring 2011 cycle are:

• Richard Robinson, Ph.D., Assistant Professor, Medical College of Wisconsin, studies the effect of interleukin-12 receptor β1 (IL12Rβ1), a receptor generated by multiple immune cells that spans the cell membrane and binds to the p40-domain of IL 12 and IL 23, and IL 12p40 homodimer. These cytokines broadly affect immune responses involved in both pathogen-driven immunity and autoimmunity. Dr. Robinson hopes to determine the relationship between levels of an isoform of IL12Rβ1, sIL12Rβ1, on the transformation of T-cells into T-effector lymphocytes in a mouse tuberculosis model and in human peripheral blood lymphocytes.
• Christopher Grigsby, a Ph.D. candidate at Duke University, is engineering polymeric nanocomplexes for oral delivery of therapeutic genes. His approach uses a gene-chitosan nanocomplex coated in a pH-sensitive polymer that helps release the gene in the intestines rather than the stomach. Gene complexes are taken up through endocytosis and migrate to the nucleus, where they instruct the cell to produce therapeutic proteins. This platform technology has broad application to diseases caused by missing proteins, for example hemophilia and diabetes. Mr. Grigsby’s abstract is titled,“Oral Delivery of the Factor VIII Gene: Immunotherapy for Hemophilia A.”
• Michael Sheard, Ph.D., Director, Flow Cytometry Core Facility, Children’s Hospital Los Angeles, plans to use his BD reagent grant to study natural killer cell-based immunotherapy for neuroblastoma. His first objective is to isolate natural killer cells from peripheral blood and expand them to clinically relevant numbers using feeder cells. The expansion process will be combined with ex vivo drug treatment using the approved myeloma drug lenalidomide. A key aspect of this study will be to observe the functional and phenotypic changes in expanded immune cell populations treated with the drug. Dr. Sheard’s abstract is titled,“Effect of Lenalidomide on the Anti-Neuroblastoma Cytotoxicity of Human Natural Killer Cells Expanded from Blood Using K562-IL21 Feeder Cells.”
• Flavia Pereira, PhD., Post-doctoral fellow at the University of Connecticut Health Center, studies the involvement of immune system cells involved in healing after a myocardial infarction. This complex process begins with the migration of monocytes and fibrocytes to the damaged heart tissue. These cells then initiate a cascade of events leading to inflammation, scar formation, and tissue remodeling. Dr. Pereira will examine the role of CD13, an aminopeptidase that mediates the trafficking of these cell types to the injured tissue. Dr. Pereira’s abstract is titled,“Role of CD13 in Wound Healing after Myocardial Infarction.”
• Doris Lambracht-Washington, Ph.D., Assistant Instructor, University of Texas Southwestern Medical Center, Dallas, Department of Neurology, is developing a preclinical-stage vaccine for treating and preventing Alzheimer’s disease (AD). The most prevalent form of dementia in the elderly, AD affects four million Americans and costs society $100 billion in medical costs and lost productivity. Dr. Lambracht-Washington will use a gene-based vaccine that will cause the subject’s own cells to manufacture the amyloid-beta antigen. She plans to test this strategy in mice and quantify the animals’ immune and inflammatory response status. Dr. Lambracht-Washington’s abstract is titled,“Phenotypic and functional characterization of T cell subsets generated in DNA Abeta42 trimer immunized mice to determine safety in immunotherapy for Alzheimer’s disease.”
• Dean Lee, M.D., Ph.D., Assistant Professor, University of Texas MD Anderson Cancer Center, investigates adoptive natural killer (NK) cell immunotherapy for treating cancer. Dr. Lee has discovered a technique for expanding functioning NK cells to clinically meaningful numbers. His BD grant project involves the enhancement of NK cell activity through interleukin-21, which induces the apoptosis inhibitor STAT3. Understanding this mechanism could lead to more effective NK-based cancer therapies. Dr. Lee’s abstract is titled,“Expanded NK Cells for Adoptive Immunotherapy.”
• Yael Korin, Ph.D., Associated Researcher, UCLA Immunogenetics Center, will identify and validate immunological biomarkers in peripheral blood that may help predict tolerance in pediatric liver transplant recipients. Dr. Korin plans to use immunophenotyping to compare characteristics of peripheral blood lymphocytes from tolerant liver transplant recipients with cells from non-tolerant and to stable recipients. The goal is to define a phenotype profile that defines immune tolerance, and hence patients who are candidates for minimization or complete withdrawal from immunosuppressive therapy. Dr. Korin’s abstract is titled,“Use of Immunophenotyping to Develop an Immune Profile of Tolerance in Pediatric Liver Transplant Recipients.”

Additional information about the BD Biosciences Grant Program is available at

About the BD Biosciences Research Grant Program
BD Biosciences’ Research Grant Program aims to reward and enable important research by providing vital funding for scientists pursuing innovative experiments to advance the scientific understanding of disease. The grant submissions are judged by a distinguished research panel of non-affiliated scientists. Through its grant program, BD Biosciences ( supports innovation in research and development as well as help enable the next generation of scientific breakthroughs.

About BD
BD ( , a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people’s health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Agency / Source: Becton, Dickinson and Company


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

BD Biosciences Announces Spring 2011 Winners of Research Grant Program

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
BD |
Contact: Alyssa Zeff - 
201-847-4358 alyssa_zeff[.]
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Becton, Dickinson and Company securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Press Releases From Becton, Dickinson and Company / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...


Visit  NAKIVO, Inc.

Visit  RightITnow Ltd


  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today